Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy.
Alemtuzumab is a lymphocyte ablative agent that may cause susceptibility to severe opportunistic infections similar to those seen in AIDS. Pathogen-specific immune reconstitution syndromes can complicate antiretroviral therapy and immune recovery in HIV-infected patients. We present the first reported case of immune reconstitution syndrome associated with T lymphocyte recovery after alemtuzumab therapy.
Ingram
Paul R
PR
Department of Infectious Diseases, Fremantle Hospital, Fremantle, Western Australia, Australia.
Howman
Rebecca
R
Leahy
Michael F
MF
Dyer
John R
JR
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003455:Cryptococcus neoformans / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D007154:Immune System Diseases / Q000276:immunology* / Q000382:microbiology; D015463:Leukemia, Prolymphocytic / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D015458:Leukemia, T-Cell / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016879:Salvage Therapy / Q000009:adverse effects; D013577:Syndrome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab